<DOC>
	<DOCNO>NCT00533910</DOCNO>
	<brief_summary>The purpose study determine whether alteration gut flora rifaximin lead improvement drive performance , psychometric test performance , quality life patient minimal hepatic encephalopathy ( MHE ) cirrhosis randomize , blind , placebo-controlled trial .</brief_summary>
	<brief_title>Rifaximin Minimal Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Age 1865 year Cirrhosis diagnose clinical ground MHE diagnose abnormality psychometric battery ( NCTA , NCTB , ICT BDT DST impair beyond 2 standard deviation know control value 3 test consider MHE ) Current driver ( valid driving license drive least 20 miles/week ) All woman childbearing potential require use effective contraception Current recent ( &lt; 6 month ) use alcohol ( AUDIT questionnaire use ; cirrhotic value &gt; 0 exclude ) positive blood alcohol level Use antibiotic within last 6 week Allergy rifaximin , rifabutin , rifampin , rifapentine Infection gastrointestinal hemorrhage within last 6 week Renal insufficiency Hepatocellular carcinoma Psychoactive drug use , include interferon concurrently Nondrivers drive less 20 miles/week Pregnancy breastfeed Excluding patient OHE : Detailed neurological examination check dysarthria , asterixis , ataxia disorientation Detailed historytaking friends/relatives take patient 's permission Minimental status examination &gt; 25 Episode overt ( clinical hepatic encephalopathy ) within 6 month Current treatment lactulose , rifaximin , zinc , metronidazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Minimal hepatic encephalopathy</keyword>
</DOC>